JP7264657B2 - Reishi processed powder - Google Patents
Reishi processed powder Download PDFInfo
- Publication number
- JP7264657B2 JP7264657B2 JP2019018629A JP2019018629A JP7264657B2 JP 7264657 B2 JP7264657 B2 JP 7264657B2 JP 2019018629 A JP2019018629 A JP 2019018629A JP 2019018629 A JP2019018629 A JP 2019018629A JP 7264657 B2 JP7264657 B2 JP 7264657B2
- Authority
- JP
- Japan
- Prior art keywords
- ganoderic acid
- powder
- reishi
- ganoderma lucidum
- content
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 240000008397 Ganoderma lucidum Species 0.000 title claims description 106
- 235000001637 Ganoderma lucidum Nutrition 0.000 title claims description 106
- 239000000843 powder Substances 0.000 title claims description 91
- RDMQPKIDHAFXKA-JNORPAGFSA-N Ganoderic Acid Am1 Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC(=O)C1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CC(=O)CC(C)C(O)=O)C)CC(=O)[C@]21C RDMQPKIDHAFXKA-JNORPAGFSA-N 0.000 claims description 34
- BSEYIQDDZBVTJY-UHFFFAOYSA-N Ganoderic acid A Natural products CC(CC(=O)CCC1CC(O)C2(C)C3=C(C(=O)CC12C)C4(C)CCC(=O)C(C)(C)C4CC3O)C(=O)O BSEYIQDDZBVTJY-UHFFFAOYSA-N 0.000 claims description 32
- RERVSJVGWKIGTJ-RQLZKMEDSA-N Ganoderic acid C2 Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1C[C@H](O)C1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CC(=O)C[C@@H](C)C(O)=O)C)C[C@H](O)[C@]21C RERVSJVGWKIGTJ-RQLZKMEDSA-N 0.000 claims description 32
- VVXZWUASDACSNQ-UHFFFAOYSA-N ganoderic acid C Natural products CC12CCC(O)C(C)(C)C1CC(O)C1=C2C(=O)CC2(C)C(C(CC(=O)CC(C)C(O)=O)C)CC(O)C21 VVXZWUASDACSNQ-UHFFFAOYSA-N 0.000 claims description 32
- ZRNXURLYNFMZRS-UHFFFAOYSA-N ganoderic acid C2 Natural products CC(CC(O)CC(C)C(=O)O)C1CC(O)C2(C)C3=C(C(=O)CC12C)C4(C)CCC(O)C(C)(C)C4CC3O ZRNXURLYNFMZRS-UHFFFAOYSA-N 0.000 claims description 32
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 26
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 17
- 229920002498 Beta-glucan Polymers 0.000 claims description 17
- YTVGSCZIHGRVAV-NJNFCIENSA-N Ganoderic acid C1 Chemical compound C([C@@]12C)CC(=O)C(C)(C)[C@@H]1C[C@H](O)C1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CC(=O)C[C@@H](C)C(O)=O)C)CC(=O)[C@]21C YTVGSCZIHGRVAV-NJNFCIENSA-N 0.000 claims description 16
- IEDDICKFTXIWIP-UHFFFAOYSA-N Ganoderic acid D Natural products CC(CC(=O)CCC1CC(=O)C2(C)C3=C(C(=O)CC12C)C4(C)CCC(=O)C(C)(C)C4CC3O)C(=O)O IEDDICKFTXIWIP-UHFFFAOYSA-N 0.000 claims description 16
- MXXWYZURWPOOOI-ZFHUNPOVSA-N ganoderic acid C1 Natural products C[C@H](CC=O)CC(=O)C[C@@H](C)[C@H]1CC(=O)[C@@]2(C)C3=C(C(=O)C[C@]12C)[C@@]4(C)CCC(=O)C(C)(C)[C@@H]4C[C@@H]3O MXXWYZURWPOOOI-ZFHUNPOVSA-N 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 12
- 235000013305 food Nutrition 0.000 claims description 7
- 239000002537 cosmetic Substances 0.000 claims description 6
- 239000000284 extract Substances 0.000 description 22
- 241000894007 species Species 0.000 description 15
- 239000011812 mixed powder Substances 0.000 description 14
- 230000000694 effects Effects 0.000 description 11
- 230000007721 medicinal effect Effects 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 10
- 230000007613 environmental effect Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 238000000605 extraction Methods 0.000 description 7
- 230000002538 fungal effect Effects 0.000 description 7
- 230000003266 anti-allergic effect Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000003276 anti-hypertensive effect Effects 0.000 description 5
- 238000012364 cultivation method Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 150000003648 triterpenes Chemical class 0.000 description 5
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 229940088679 drug related substance Drugs 0.000 description 4
- 238000010298 pulverizing process Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229930182735 Ganoderic acid Natural products 0.000 description 2
- 241000222336 Ganoderma Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 230000036436 anti-hiv Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 210000003056 antler Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 230000002434 immunopotentiative effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- 241000221198 Basidiomycota Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Landscapes
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Cosmetics (AREA)
Description
本発明は、霊芝加工粉に関する。 The present invention relates to processed powder of Ganoderma lucidum.
霊芝は、その薬効効果が注目され、顆粒、錠剤、カプセル等の形態で健康補助食品として提供されている。 Ganoderma lucidum has attracted attention for its medicinal effects, and is provided as health supplements in the form of granules, tablets, capsules, and the like.
霊芝には、β－グルカン、トリテルペン類等が含まれており、これらを有効成分として様々な薬効効果が発揮されると考えられている。例えば、トリテルペン類であるガノデリン酸Ａは、血圧上昇抑制（アンギオテンシン転換酵素（ＡＣＥ）阻害）作用等を有すること、ガノデリン酸Ｃ２は、血圧上昇抑制（ＡＣＥ阻害）作用、抗アレルギー（抗ヒスタミン）作用等を有することが知られている（例えば、特許文献１及び２）。 Ganoderma lucidum contains β-glucan, triterpenes, etc., and it is believed that these active ingredients exert various medicinal effects. For example, ganoderic acid A, which is a triterpene, has a blood pressure elevation suppression (angiotensin converting enzyme (ACE) inhibition) action, etc., and ganoderic acid C2 has a blood pressure elevation suppression (ACE inhibition) action and an anti-allergic (antihistamine) action. etc. (for example, Patent Documents 1 and 2).
本発明は、霊芝の有する薬効効果が高められた霊芝加工粉の提供を目的とする。 An object of the present invention is to provide processed powder of Ganoderma lucidum with enhanced medicinal effects of Ganoderma lucidum.
本発明は、ガノデリン酸Ａの含有量が１．２ｍｇ／ｇ以上であり、かつガノデリン酸Ｃ２の含有量が１．３ｍｇ／ｇ以上である、霊芝加工粉に関する。 The present invention relates to processed powder of ganoderma lucidum having a content of ganoderic acid A of 1.2 mg/g or more and a content of ganoderic acid C2 of 1.3 mg/g or more.
本発明に係る霊芝加工粉は、ガノデリン酸Ａ及びガノデリン酸Ｃ２の含有量が高められており、これにより霊芝の有する薬効効果が高められたものとなる。ガノデリン酸Ａには、血圧上昇抑制作用に加え、例えば、抗ヒト免疫不全ウイルス（ＨＩＶ）作用、抗腫瘍作用、コレステロール低下作用、肝障害改善作用等が知られている。ガノデリン酸Ｃ２には、例えば、血圧上昇抑制作用、抗アレルギー作用等が知られている。本発明に係る霊芝加工粉は、ガノデリン酸Ａ及びガノデリン酸Ｃ２の含有量が高められているため、これらの作用効果が高められたものとなる。 The processed powder of ganoderma lucidum according to the present invention has increased contents of ganoderic acid A and ganoderic acid C2, which enhances the medicinal effects of ganoderma lucidum. Ganoderic acid A is known to have anti-human immunodeficiency virus (HIV) action, anti-tumor action, cholesterol-lowering action, hepatopathy-improving action, and the like, in addition to antihypertensive action. Ganoderic acid C2 is known to have, for example, an antihypertensive action, an antiallergic action, and the like. Since the processed powder of ganoderma lucidum according to the present invention has increased contents of ganoderic acid A and ganoderic acid C2, these actions and effects are enhanced.
上記霊芝加工粉は、更にガノデリン酸Ｃ１の含有量が０．５ｍｇ／ｇ以上であってもよい。ガノデリン酸Ｃ１には、例えば、血圧上昇抑制（ＡＣＥ阻害）作用、抗アレルギー（抗ヒスタミン）作用等が知られている。ガノデリン酸Ｃ１の含有量を高めることによって、これらの作用効果がより一層高められる。 The processed powder of Ganoderma lucidum may further contain 0.5 mg/g or more of ganoderic acid C1. Ganoderic acid C1 is known to have, for example, an antihypertensive (ACE inhibitory) action, an antiallergic (antihistamine) action, and the like. By increasing the content of ganoderic acid C1, these effects are further enhanced.
上記霊芝加工粉は、更にβ－グルカンの含有量が０．４５ｇ／ｇ以上であってもよい。β－グルカンには、抗腫瘍作用、免疫増強作用等が知られている。β－グルカンの含有量を高めることによって、これらの作用効果がより一層高められる。 The Reishi processed powder may further have a β-glucan content of 0.45 g/g or more. β-Glucan is known to have antitumor action, immunopotentiating action and the like. By increasing the content of β-glucan, these effects are further enhanced.
本発明に係る霊芝加工粉は、生体に対して安全であり、また霊芝の有する薬効効果が高められているため、例えば、食品組成物、化粧品組成物に好適に使用することができる。したがって、本発明はまた、上述した霊芝加工粉を含有する、食品組成物にも関する。本発明はさらに、上述した霊芝加工粉を含有する、化粧品組成物にも関する。 The processed powder of Ganoderma lucidum according to the present invention is safe to the living body, and the medicinal effect of Ganoderma lucidum is enhanced. Accordingly, the present invention also relates to a food composition containing the above-described processed powder of ganoderma lucidum. The present invention further relates to a cosmetic composition containing the processed powder of ganoderma lucidum as described above.
本発明によれば、ガノデリン酸Ａ及びガノデリン酸Ｃ２の含有量が高められ、これにより霊芝の有する薬効効果が高められた霊芝加工粉の提供が可能となる。 According to the present invention, the contents of ganoderic acid A and ganoderic acid C2 are increased, so that it is possible to provide processed powder of ganoderma lucidum with enhanced medicinal effects of ganoderma lucidum.
以下、本発明を実施するための形態について詳細に説明する。ただし、本発明は以下の実施形態に限定されるものではない。 DETAILED DESCRIPTION OF THE INVENTION Embodiments for carrying out the present invention will be described in detail below. However, the present invention is not limited to the following embodiments.
〔霊芝加工粉〕
本実施形態に係る霊芝加工粉は、ガノデリン酸Ａの含有量が１．２ｍｇ／ｇ以上であり、かつガノデリン酸Ｃ２の含有量が１．３ｍｇ／ｇ以上である。
[Reishi processed powder]
The processed powder of ganoderma lucidum according to the present embodiment has a content of ganoderic acid A of 1.2 mg/g or more and a content of ganoderic acid C2 of 1.3 mg/g or more.
本明細書において、「霊芝」には、マンネンタケ属（Ｇａｎｏｄｅｒｍａ）に属する担子菌の子実体が含まれる。霊芝の種類としては、例えば、赤霊芝、黒霊芝、紫霊芝、青霊芝、黄霊芝及び白霊芝が挙げられる。本発明で使用する霊芝としては、ガノデルマ ルキドゥム（Ｇａｎｏｄｅｒｍａ ｌｕｃｉｄｕｍ）に属する霊芝であることが好ましい。ガノデルマ ルキドゥムに属する霊芝は、マンネンタケ（万年茸）又はサイワイタケ（幸茸）とも呼ばれる。万年茸は、生育条件によって、鹿角霊芝（鹿角状に子実体が生育したもの）と呼ばれる子実体を形成することがある。 As used herein, "reishi" includes fruiting bodies of basidiomycetes belonging to the genus Ganoderma. Types of reishi include, for example, red reishi, black reishi, purple reishi, blue reishi, yellow reishi, and white reishi. The reishi mushroom used in the present invention is preferably a reishi mushroom belonging to Ganoderma lucidum. Reishi mushrooms belonging to Ganoderma lucidum are also called Ganoderma lucidum or Saiwaitake. Mannen mushrooms sometimes form a fruiting body called antler reishi (a fruiting body grown in the shape of an antler) depending on the growth conditions.
本明細書において、「霊芝加工粉」とは、霊芝の子実体の一部（「一部」には、エキス等の抽出物も含まれる。）又は全部を加工して粉末状にしたものを意味する。霊芝加工粉としては、例えば、霊芝の子実体そのものを粉末にしたもの（本明細書において「微粉末」とも呼ぶ。）、霊芝の子実体から抽出したエキスを粉末にしたもの（本明細書において「エキス粉末」とも呼ぶ。）が例示される。霊芝加工粉には、例えば、微粉末とエキス粉末の混合粉末等の２種以上の粉末を混合したものも含まれる。 As used herein, the term "processed powder of reishi" means a part of the fruiting body of reishi ("part" includes extracts such as extracts) or the whole, which has been processed into a powder. means something Reishi processed powder includes, for example, powdered reishi fruiting body itself (also referred to as “fine powder” in this specification) and powdered extract extracted from reishi fruiting body (this product). Also referred to as "extract powder" in the specification.) is exemplified. Reishi processed powder includes, for example, a mixture of two or more powders such as a mixed powder of fine powder and extract powder.
「粉末」又は「粉末状」とは、嵩密度が０．１８～０．８０ｇ／ｃｃの範囲にあることをいう。 "Powder" or "powder form" means that the bulk density is in the range of 0.18 to 0.80 g/cc.
嵩密度は、次のようにして測定することができる。まず、所定の容積の容器に、試料（霊芝加工粉等）を上方から注ぎ、容器の上端面上方にまで盛り上がるようにする。このとき、過大な試料の混入を防ぐため、容器に注ぐ試料は、所定メッシュサイズの篩を通すのが好ましい。そして、上端面より盛り上がった試料を、板等によって容器の上端面に沿って摺り切る。この後、容器内に残った試料の重量Ｗを計測し、これを容器の容積Ｖで除算したものが、嵩密度Ｘとなる。
Ｘ＝Ｗ／Ｖ［ｇ／ｃｃ］
Bulk density can be measured as follows. First, a sample (reishi processed powder, etc.) is poured from above into a container with a predetermined volume so that the sample rises above the upper end surface of the container. At this time, the sample to be poured into the container is preferably passed through a sieve having a predetermined mesh size in order to prevent an excessively large sample from being mixed. Then, the sample protruding from the upper end face is scraped off along the upper end face of the container with a plate or the like. After that, the weight W of the sample remaining in the container is measured and divided by the volume V of the container to obtain the bulk density X.
X = W/V [g/cc]
ガノデリン酸Ａは、霊芝に含まれるトリテルペン類の一つであり、下記式（１）で表される化合物である。
本実施形態に係る霊芝加工粉におけるガノデリン酸Ａの含有量は、霊芝加工粉全量を基準として、１．２ｍｇ／ｇ以上（すなわち、霊芝加工粉１ｇあたりガノデリン酸Ａが１．２ｍｇ以上含まれる。）である。ガノデリン酸Ａの含有量は、１．３ｍｇ／ｇ以上であってもよく、１．４ｍｇ／ｇ以上であってもよく、１．５ｍｇ／ｇ以上であってもよく、１．６ｍｇ／ｇ以上であってもよく、１．７ｍｇ／ｇ以上であってもよく、１．８ｍｇ／ｇ以上であってもよく、１．９ｍｇ／ｇ以上であってもよく、２．０ｍｇ／ｇ以上であってもよく、２．１ｍｇ／ｇ以上であってもよく、２．２ｍｇ／ｇ以上であってもよく、２．３ｍｇ／ｇ以上であってもよく、２．４ｍｇ／ｇ以上であってもよく、２．５ｍｇ／ｇ以上であってもよい。 The content of ganoderic acid A in the processed powder of Ganoderma lucidum according to the present embodiment is 1.2 mg/g or more based on the total amount of processed powder of Ganoderma lucidum. included.). The content of ganoderic acid A may be 1.3 mg/g or more, 1.4 mg/g or more, 1.5 mg/g or more, or 1.6 mg/g or more. 1.7 mg/g or more, 1.8 mg/g or more, 1.9 mg/g or more, or 2.0 mg/g or more may be 2.1 mg/g or more, may be 2.2 mg/g or more, may be 2.3 mg/g or more, may be 2.4 mg/g or more It may be 2.5 mg/g or more.
ガノデリン酸Ａは、例えば、血圧上昇抑制作用、抗ＨＩＶ作用、抗腫瘍作用、コレステロール低下作用、肝障害改善作用、抗アレルギー作用等の作用効果を発揮する。ガノデリン酸Ａの含有量が高い程、これらの作用効果に基づく薬効効果が高くなる。本実施形態に係る霊芝加工粉におけるガノデリン酸Ａの含有量の上限に特に制限はないが、通常１０．０ｍｇ／ｇ以下である。 Ganoderic acid A exerts effects such as, for example, blood pressure elevation suppressing action, anti-HIV action, anti-tumor action, cholesterol-lowering action, hepatopathy-ameliorating action, and anti-allergic action. The higher the content of ganoderic acid A, the higher the medicinal effect based on these effects. Although there is no particular upper limit for the content of ganodernic acid A in the processed powder of ganoderma lucidum according to the present embodiment, it is usually 10.0 mg/g or less.
ガノデリン酸Ｃ２は、霊芝に含まれるトリテルペン類の一つであり、下記式（２）で表される化合物である。
本実施形態に係る霊芝加工粉におけるガノデリン酸Ｃ２の含有量は、霊芝加工粉全量を基準として、１．３ｍｇ／ｇ以上（すなわち、霊芝加工粉１ｇあたりガノデリン酸Ｃ２が１．３ｍｇ以上含まれる。）である。ガノデリン酸Ｃ２の含有量は、１．４ｍｇ／ｇ以上であってもよく、１．５ｍｇ／ｇ以上であってもよく、１．６ｍｇ／ｇ以上であってもよく、１．７ｍｇ／ｇ以上であってもよく、１．８ｍｇ／ｇ以上であってもよく、１．９ｍｇ／ｇ以上であってもよく、２．０ｍｇ／ｇ以上であってもよい。 The content of ganoderic acid C2 in the processed powder of reishi mushroom according to the present embodiment is 1.3 mg/g or more based on the total amount of processed powder of reishi mushroom (i.e., 1.3 mg or more of ganoderic acid C2 per 1 g of processed powder of reishi mushroom). included.). The content of ganoderic acid C2 may be 1.4 mg/g or more, 1.5 mg/g or more, 1.6 mg/g or more, or 1.7 mg/g or more. , 1.8 mg/g or more, 1.9 mg/g or more, or 2.0 mg/g or more.
ガノデリン酸Ｃ２は、例えば、血圧上昇抑制作用、抗アレルギー作用、抗糖尿病等の作用効果を発揮する。ガノデリン酸Ｃ２の含有量が高い程、これらの作用効果に基づく薬効効果が高くなる。本実施形態に係る霊芝加工粉におけるガノデリン酸Ｃ２の含有量の上限に特に制限はないが、通常１０．０ｍｇ／ｇ以下である。 Ganoderic acid C2 exerts effects such as an antihypertensive action, an antiallergic action, and an antidiabetic action, for example. The higher the content of ganoderic acid C2, the higher the medicinal effect based on these effects. Although there is no particular upper limit for the content of ganoderic acid C2 in the processed powder of ganoderma lucidum according to the present embodiment, it is usually 10.0 mg/g or less.
本実施形態に係る霊芝加工粉は、更にガノデリン酸Ｃ１の含有量が０．５ｍｇ／ｇ以上であることが好ましい。 It is preferable that the processed powder of Ganoderma lucidum according to the present embodiment further has a content of ganoderic acid C1 of 0.5 mg/g or more.
ガノデリン酸Ｃ１は、霊芝に含まれるトリテルペン類の一つであり、下記式（３）で表される化合物である。
本実施形態に係る霊芝加工粉におけるガノデリン酸Ｃ１の含有量は、霊芝加工粉全量を基準として、０．５ｍｇ／ｇ以上（すなわち、霊芝加工粉１ｇあたりガノデリン酸Ｃ１が０．５ｍｇ以上含まれる。）であってよく、０．６ｍｇ／ｇ以上であってもよく、０．７ｍｇ／ｇ以上であってもよく、０．８ｍｇ／ｇ以上であってもよく、０．９ｍｇ／ｇ以上であってもよく、１．０ｍｇ／ｇ以上であってもよく、１．１ｍｇ／ｇ以上であってもよく、１．２ｍｇ／ｇ以上であってもよく、１．３ｍｇ／ｇ以上であってもよく、１．４ｍｇ／ｇ以上であってもよく、１．５ｍｇ／ｇ以上であってもよい。 The content of ganoderic acid C1 in the processed powder of reishi mushroom according to the present embodiment is 0.5 mg/g or more based on the total amount of processed powder of reishi mushroom (i.e., 0.5 mg or more of ganoderic acid C1 per 1 g of processed powder of reishi mushroom). ), may be 0.6 mg/g or more, may be 0.7 mg/g or more, may be 0.8 mg/g or more, may be 0.9 mg/g 1.0 mg/g or more, 1.1 mg/g or more, 1.2 mg/g or more, or 1.3 mg/g or more 1.4 mg/g or more, or 1.5 mg/g or more.
ガノデリン酸Ｃ１は、例えば、血圧上昇抑制作用、抗アレルギー作用、抗ＨＩＶ作用等の作用効果を発揮する。ガノデリン酸Ｃ１の含有量が高い程、これらの作用効果に基づく薬効効果が高くなる。本実施形態に係る霊芝加工粉におけるガノデリン酸Ｃ１の含有量の上限に特に制限はないが、通常１０．０ｍｇ／ｇ以下である。 Ganoderic acid C1 exerts effects such as, for example, an antihypertensive action, an anti-allergic action, an anti-HIV action, and the like. The higher the content of ganoderic acid C1, the higher the medicinal effect based on these effects. Although there is no particular upper limit for the content of ganoderic acid C1 in the processed powder of ganoderma lucidum according to the present embodiment, it is usually 10.0 mg/g or less.
本実施形態に係る霊芝加工粉は、更にβ－グルカンの含有量が０．４５ｇ／ｇ以上であることが好ましい。 The processed powder of Ganoderma lucidum according to the present embodiment preferably has a β-glucan content of 0.45 g/g or more.
本実施形態に係る霊芝加工粉におけるβ－グルカンの含有量は、霊芝加工粉全量を基準として、０．４５ｇ／ｇ以上（すなわち、霊芝加工粉１ｇあたりβ－グルカンが０．４５ｇ以上含まれる。）であってよく、０．４６ｇ／ｇ以上であってもよく、０．４７ｇ／ｇ以上であってもよく、０．４８ｇ／ｇ以上であってもよい。 The content of β-glucan in the reishi processed powder according to the present embodiment is 0.45 g/g or more based on the total amount of reishi processed powder (that is, 0.45 g or more of β-glucan per 1 g of reishi processed powder). included.), may be 0.46 g/g or more, may be 0.47 g/g or more, or may be 0.48 g/g or more.
β－グルカンは、例えば、抗腫瘍作用、免疫増強作用、コレステロール正常化作用等の作用効果を発揮する。β－グルカンの含有量が高い程、これらの作用効果に基づく薬効効果が高くなる。本実施形態に係る霊芝加工粉におけるβ－グルカンの含有量の上限に特に制限はないが、通常６０ｇ／ｇ以下である。 β-Glucan exerts effects such as antitumor action, immunopotentiating action, and cholesterol normalizing action. The higher the β-glucan content, the higher the medicinal effect based on these effects. Although there is no particular upper limit for the content of β-glucan in the processed powder of Reishi mushroom according to the present embodiment, it is usually 60 g/g or less.
本実施形態に係る霊芝加工粉は、粉末として提供されてもよく、カプセルに充填して提供されてもよく、バインダ等を混合して打錠成形して提供されてもよい。 The ganoderma lucidum processed powder according to the present embodiment may be provided as a powder, may be provided by being filled in a capsule, or may be provided by mixing a binder or the like and molding into tablets.
〔霊芝加工粉の製造方法〕
本実施形態に係る霊芝加工粉は、ガノデリン酸Ａ及びガノデリン酸Ｃ２の含有量が高い霊芝の子実体の一部（「一部」には、エキス等の抽出物も含まれる。）又は全部を加工して粉末状にすることで製造することができる。
[Manufacturing method of Reishi processed powder]
The processed powder of ganoderma lucidum according to the present embodiment is a part of the fruiting body of ganoderma lucidum having a high content of ganoderic acid A and ganoderic acid C2 ("a part" also includes extracts such as extracts), or It can be manufactured by processing the whole into a powder.
ガノデリン酸Ａ及びガノデリン酸Ｃ２の含有量が高い霊芝の子実体は、例えば、ガノデリン酸Ａ及びガノデリン酸Ｃ２の含有量が高い原体種を交配し、ガノデリン酸Ａ及びガノデリン酸Ｃ２の含有量がより高められた原体種を選抜し、当該原体種を栽培して霊芝原体（子実体）を得る方法、後述するように栽培条件を適当に設定することにより、得られる霊芝原体（子実体）のガノデリン酸Ａ及びガノデリン酸Ｃ２の含有量を高める方法等により得ることができる。 The fruiting body of Ganoderma lucidum with high ganoderic acid A and ganoderic acid C2 contents is obtained, for example, by crossing the progenitor species with high ganoderic acid A and ganoderic acid C2 contents, A method of selecting a progenitor species with a higher concentration of reishi and cultivating it to obtain a reishi progenitor (fruiting body); It can be obtained by a method of increasing the content of ganoderic acid A and ganoderic acid C2 in (fruiting body).
ガノデリン酸Ａ及びガノデリン酸Ｃ２の含有量がより高められた原体種は、例えば、入手可能な種々の霊芝原体（例えば、一般的に市場に流通している種々の霊芝原体）の成分分析を行い、その結果、相対的にガノデリン酸Ａ及びガノデリン酸Ｃ２の含有量が高い原体種（例えば、ガノデリン酸Ａ及びガノデリン酸Ｃ２の含有量が、平均値の１．２倍、１．３倍、１．４倍又は１．５倍の原体種）を選別すること、次いで、例えば、選別した２種の原体種を交配し、得られた交配種をガノデリン酸Ａ及びガノデリン酸Ｃ２の含有量を指標としてスクリーニングすることで、選抜することができる。 Ganodelic acid A and ganodelic acid C2-enriched drug substance species are, for example, components of various available Ganoderma lucidum drug substances (e.g., various Ganoderma lucidum drug substances commonly available on the market). Analysis was performed, and as a result, the drug substance species with relatively high contents of ganoderic acid A and ganoderic acid C2 (eg, the content of ganoderic acid A and ganoderic acid C2 was 1.2 times the average value, 1. 3-fold, 1.4-fold or 1.5-fold bulk species), and then, for example, crossing the two selected bulk species, the resulting hybrid being ganoderic acid A and ganoderic acid It can be selected by screening using the content of C2 as an index.
ガノデリン酸Ａ及びガノデリン酸Ｃ２の含有量がより高められた原体種の選抜にあたっては、ガノデリン酸Ａ及びガノデリン酸Ｃ２の含有量に加えて、更にガノデリン酸Ｃ１及び／又はβ－グルカンの含有量を指標としたスクリーニングを併せて行ってもよい。 In the selection of a bulk species with a higher content of ganoderic acid A and ganoderic acid C2, in addition to the content of ganoderic acid A and ganoderic acid C2, the content of ganoderic acid C1 and / or β-glucan may be performed together with screening using as an index.
ガノデリン酸Ａ、ガノデリン酸Ｃ２、ガノデリン酸Ｃ１及びβ－グルカンの含有量は、例えば、後述の実施例に記載の方法で測定することができる。 The contents of ganoderic acid A, ganoderic acid C2, ganoderic acid C1, and β-glucan can be measured, for example, by the methods described in Examples below.
子実体の栽培方法は、例えば、原体種の菌床を得る工程と、得られた菌床から子実体を生育させる工程とを含む。 The method for cultivating fruiting bodies includes, for example, a step of obtaining a fungal bed of the protozoan and a step of growing fruiting bodies from the obtained fungal bed.
菌床を得る工程では、例えば、おが屑、米ぬか、ふすま等を混ぜたもの（これを培地と称する）を培養袋又は広口ビン等の容器に充填した後、この培地に原体種の菌を植え付け、これを一定期間培養させる。培養の際の温度（環境温度）は、１５～３５℃であってよい。培養期間は、１４～３０日間であってよい。これにより、原体種の菌糸が容器内の培地に蔓延し、いわゆる菌床が得られる。 In the process of obtaining a fungal bed, for example, a mixture of sawdust, rice bran, bran, etc. (this is called a medium) is filled in a container such as a culture bag or a wide-mouthed bottle, and then the active ingredient fungus is planted in this medium. , which is cultured for a certain period of time. The temperature (environmental temperature) during culture may be 15 to 35°C. The culture period may be 14-30 days. As a result, mycelium of the protozoan species spreads over the culture medium in the container, and a so-called fungal bed is obtained.
子実体を生育させる工程では、得られた菌床を、所定範囲内の湿度・温度・照度環境に維持することで菌床から万年茸の子実体が生えてくるので、この環境を一定期間維持して所望の大きさに生育させる。生育の際の湿度（環境湿度）は、５０～１００％ＲＨであってよい。生育の際の温度（環境温度）は、２０～３５℃であってよい。生育の際の照度は、１０～５００ｌｘであってよい。生育期間は、３０～６０日間であってよい。 In the process of growing the fruiting body, by maintaining the obtained fungal bed in an environment of humidity, temperature, and light intensity within the specified range, the fruiting body of the Mannen Mushroom grows from the fungal bed. Maintain and grow to desired size. Humidity during growth (environmental humidity) may be 50 to 100% RH. The temperature during growth (environmental temperature) may be 20-35°C. The illumination intensity during growth may be 10-500 lx. The growing period may be 30-60 days.
得られる子実体のガノデリン酸Ａ及びガノデリン酸Ｃ２の含有量を高める観点から、生育の際の湿度（環境湿度）は、８０～１００％ＲＨであることが好ましく、９０～１００％ＲＨであることがより好ましく、９５～１００％ＲＨであることが更に好ましい。同様の観点から、生育の際の照度は、１００～５００ｌｘであることが好ましく、２００～５００ｌｘであることがより好ましい。環境湿度及び照度の両方をより高く設定することで、得られる子実体のガノデリン酸Ａ及びガノデリン酸Ｃ２の含有量をより一層高めることができる。 From the viewpoint of increasing the content of ganoderic acid A and ganoderic acid C2 in the resulting fruiting body, the humidity (environmental humidity) during growth is preferably 80 to 100% RH, more preferably 90 to 100% RH. is more preferred, and 95 to 100% RH is even more preferred. From the same point of view, the illuminance during growth is preferably 100 to 500 lx, more preferably 200 to 500 lx. By setting both the environmental humidity and the illuminance higher, the content of ganoderic acid A and ganoderic acid C2 in the obtained fruiting body can be further increased.
栽培により得られた子実体は、例えば、以下の方法で霊芝加工粉に加工することができる。 Fruiting bodies obtained by cultivation can be processed into processed powder of Reishi mushroom by, for example, the following method.
（霊芝の微粉末）
得られた子実体を菌床から切り取り、所定期間乾燥させることで、乾燥子実体が得られる。次に、乾燥子実体を、適当な大きさ（例えば、～５ｃｍ程度）にカットした後、回転刃の付いた破砕装置等で粗粉砕する。次に、粗粉砕した粉末を、乾式ジェットミル等の粉砕手段によって微粉砕して、霊芝の微粉末を得ることができる。
(Ganoderma lucidum powder)
The obtained fruiting body is cut from the fungal bed and dried for a predetermined period to obtain a dried fruiting body. Next, the dried fruiting body is cut into a suitable size (for example, about 5 cm), and then coarsely pulverized by a crusher equipped with a rotating blade. Next, the coarsely pulverized powder is finely pulverized by pulverizing means such as a dry jet mill to obtain a fine powder of reishi mushroom.
粗粉砕及び微粉砕する際の条件は、得られる微粉末の嵩密度が０．２０～０．８０ｇ／ｃｃの範囲になるよう設定するのが好ましい。嵩密度は、霊芝のような菌糸の集合体からなる試料の粉砕レベルをより正確に反映した指標となるためである。嵩密度は、上述した方法により測定される。嵩密度は、例えば、粉砕時間を変更することにより、制御することができる（粉砕時間を長くすると嵩密度は大きくなる）。 The conditions for coarsely pulverizing and finely pulverizing are preferably set so that the resulting fine powder has a bulk density in the range of 0.20 to 0.80 g/cc. This is because the bulk density is an index that more accurately reflects the pulverization level of a sample consisting of an aggregate of hyphae such as reishi mushrooms. Bulk density is measured by the method described above. Bulk density can be controlled, for example, by changing the grinding time (longer grinding time increases bulk density).
（エキス粉末）
エキス粉末は、例えば、上述のようにして調製した微粉末をエキス抽出し、抽出時に生じる残渣とエキスを含んだ状態のスラリー状エキスを乾燥することで得ることができる。
(extract powder)
The extract powder can be obtained, for example, by subjecting the fine powder prepared as described above to extraction, and drying the extract slurry containing the residue and extract generated during the extraction.
エキス抽出は、例えば、熱水抽出、エタノール抽出、含水エタノール抽出等であってよい。含水エタノールは、例えば、エタノール濃度が３０～９０ｖ／ｖ％であってよい。抽出時の温度は、例えば、３０～８０℃である。エキス抽出後、抽出に使用した溶媒を蒸発乾燥させてもよい。 The extract extraction may be, for example, hot water extraction, ethanol extraction, hydrous ethanol extraction, or the like. The hydrous ethanol may have, for example, an ethanol concentration of 30 to 90 v/v%. The temperature during extraction is, for example, 30 to 80°C. After extraction of the extract, the solvent used for extraction may be evaporated to dryness.
抽出されたエキスに、抽出の際に生じる残渣を投入してスラリー状エキスを得る。そして、スラリー状エキスを、スプレードライヤ等で乾燥することでエキス粉末を得る。 A slurry-like extract is obtained by adding the residue generated during the extraction to the extracted extract. Then, the slurry-like extract is dried with a spray dryer or the like to obtain an extract powder.
（混合粉末）
混合粉末は、例えば、上述のようにして調製した微粉末及びエキス粉末を混合することで得ることができる。混合割合に特に制限はなく、微粉末とエキス粉末の比として、１：９～９：１の範囲であってよく、２：８～８：２の範囲であってよく、３：７～７：３の範囲であってよく、１：２～２：１の範囲であってよく、４：６～６：４の範囲であってもよい。
(mixed powder)
A mixed powder can be obtained, for example, by mixing the fine powder and the extract powder prepared as described above. The mixing ratio is not particularly limited, and the ratio of fine powder to extract powder may be in the range of 1:9 to 9:1, 2:8 to 8:2, or 3:7 to 7. :3, 1:2 to 2:1, 4:6 to 6:4.
〔霊芝加工粉の用途〕
本実施形態に係る霊芝加工粉は、生体に対して安全であり、また霊芝の有する薬効効果が高められているため、例えば、食品組成物、化粧品組成物に好適に使用することができる。
[Uses of reishi processed powder]
The processed powder of Ganoderma lucidum according to the present embodiment is safe to the living body and has enhanced medicinal effects of Ganoderma lucidum. Therefore, it can be suitably used in food compositions and cosmetic compositions, for example. .
本発明の一側面として、本発明に係る霊芝加工粉を含有する食品組成物が提供される。食品組成物には、一般食品、健康食品、機能性食品、栄養補助食品、サプリメント及び特定保健用食品等が含まれる。 As one aspect of the present invention, there is provided a food composition containing the processed powder of ganoderma lucidum according to the present invention. Food compositions include general foods, health foods, functional foods, dietary supplements, supplements, foods for specified health uses, and the like.
本発明の更に別の側面として、本発明に係る霊芝加工粉を含有する化粧品組成物が提供される。化粧品組成物には、化粧品、薬用化粧品等が含まれる。 As still another aspect of the present invention, there is provided a cosmetic composition containing the processed powder of ganoderma lucidum according to the present invention. Cosmetic compositions include cosmetics, cosmeceuticals, and the like.
以下、本発明を実施例に基づいてより具体的に説明する。ただし、本発明は以下の実施例に限定されるものではない。 EXAMPLES The present invention will be described in more detail below based on examples. However, the present invention is not limited to the following examples.
〔霊芝原体の栽培〕
原体種Ａ及び原体種Ｂを使用し、それぞれ下記に示す栽培条件Ｐ及び栽培条件Ｑの条件下で栽培し、霊芝原体（子実体）を得た。
[Cultivation of Ganoderma lucidum]
Using the active ingredient A and the active ingredient B, they were cultivated under the following cultivation conditions P and Q, respectively, to obtain an active body (fruiting body) of Ganoderma lucidum.
（原体種）
まず、一般的に市場に流通している種々の霊芝原体の成分分析を行った。ガノデリン酸Ａ及びガノデリン酸Ｃ２の含有量の平均値を算出し、ガノデリン酸Ａ及びガノデリン酸Ｃ２の含有量が平均値の１．２倍以上の原体種を２種選抜した。選抜した２種の原体種を交配し、ガノデリン酸Ａ及びガノデリン酸Ｃ２の含有量がより高められた原体種（交配種）を選抜した。これを原体種Ｂとした。また、ガノデリン酸Ａ及びガノデリン酸Ｃ２の含有量が平均値の１．２倍未満であり、交配していない原体種を原体種Ａとした。
(prototype species)
First, we analyzed the components of various Ganoderma medicinal products that are generally available on the market. The average contents of ganoderic acid A and ganoderic acid C2 were calculated, and two active ingredients having ganoderic acid A and ganoderic acid C2 contents of 1.2 times or more of the average contents were selected. The two selected progenitor seeds were crossed to select a progenitor seed (hybrid) with higher contents of ganoderic acid A and ganoderic acid C2. This was designated as Prototype B. In addition, the content of ganoderic acid A and ganoderic acid C2 was less than 1.2 times the average value, and the uncrossed protozoan was designated as protozoan A.
（栽培条件）
栽培条件Ｐ：子実体を生育させる工程おいて、子実体の生育環境を一定期間維持して所望の大きさに生育させる際の湿度（環境湿度）は、５０～９０％ＲＨ、生育の際の温度（環境温度）は、２０～３５℃、生育の際の照度は、１０～２００ｌｘである。
栽培条件Ｑ：子実体を生育させる工程おいて、子実体の生育環境を一定期間維持して所望の大きさに生育させる際の湿度（環境湿度）は、９５～１００％ＲＨ、生育の際の温度（環境温度）は、２５～３５℃、生育の際の照度は、２００～５００ｌｘである。
栽培条件Ｐは、従来の栽培方法に相当する。栽培条件Ｑは本発明における実施例の栽培方法であり、従来よりも比較的湿度が高く、かつ照度を高めたことを特徴としている。
(Cultivation conditions)
Cultivation condition P: In the step of growing the fruiting body, the humidity (environmental humidity) when maintaining the growing environment of the fruiting body for a certain period and growing it to a desired size is 50 to 90% RH. The temperature (environmental temperature) is 20 to 35° C., and the illuminance during growth is 10 to 200 lx.
Cultivation condition Q: In the step of growing the fruiting body, the humidity (environmental humidity) when maintaining the growing environment of the fruiting body for a certain period and growing it to a desired size is 95 to 100% RH, The temperature (environmental temperature) is 25-35° C., and the illumination during growth is 200-500 lx.
Cultivation condition P corresponds to a conventional cultivation method. Cultivation condition Q is the cultivation method of the embodiment of the present invention, which is characterized by relatively higher humidity and higher illuminance than conventional ones.
〔製造例１：霊芝加工粉（霊芝の微粉末）の製造〕
収穫後、乾燥した霊芝原体（乾燥子実体）を～５ｃｍ程度にカットし、オリエントミルにより３ｍｍ角程度に粗粉砕した。粗粉砕した粉末を乾式ジェットミルで更に粉砕し、霊芝の微粉末を得た。微粉末の嵩密度は、０．２０～０．８０ｇ／ｃｃの範囲内であった。
[Production Example 1: Production of reishi processed powder (fine powder of reishi)]
After harvesting, the dried Ganoderma lucidum (dried fruiting body) was cut into pieces of about 5 cm and coarsely pulverized into pieces of about 3 mm square by an orient mill. The coarsely pulverized powder was further pulverized with a dry jet mill to obtain a fine powder of reishi mushroom. The bulk density of the fine powder was in the range of 0.20-0.80 g/cc.
微粉末の嵩密度は、以下のようにして測定した。体積２０ｍＬの測定用セルに４２メッシュの目開きの篩を通して微粉末を落下させ、測定用セルの上端面より盛り上がった微粉末を板によって測定用セルの上端面に沿って摺り切った。この状態で体積２０ｍＬあたりの微粉末の重量を測定し、嵩密度を算出した。 The bulk density of the fine powder was measured as follows. The fine powder was dropped through a 42-mesh sieve into a measuring cell having a volume of 20 mL, and the fine powder rising from the upper end surface of the measuring cell was scraped off along the upper end surface of the measuring cell with a plate. In this state, the weight of the fine powder per 20 mL volume was measured to calculate the bulk density.
〔製造例２：霊芝加工粉（エキス粉末）の製造〕
まず、製造例１と同様にして、霊芝の微粉末を得た。得られた微粉末を、含水エタノール溶液（エタノール濃度３０ｖ／ｖ％）でエキス抽出し、残渣を含んだ状態のスラリー状エキスをスプレードライにより乾燥し、エキス粉末を得た。乾燥処理は入熱１８５℃、排熱９５℃、ノズル口径１．３ｍｍ、噴霧圧力１７０ｋｇ／ｃｍ２、溶液濃度１０～１５％で行った。
[Production Example 2: Production of Reishi processed powder (extract powder)]
First, in the same manner as in Production Example 1, a fine powder of Reishi mushroom was obtained. The resulting fine powder was extracted with a water-containing ethanol solution (ethanol concentration: 30 v/v %), and the slurry-like extract containing the residue was dried by spray drying to obtain an extract powder. The drying treatment was carried out at a heat input of 185° C., an exhaust heat of 95° C., a nozzle diameter of 1.3 mm, a spray pressure of 170 kg/cm 2 and a solution concentration of 10 to 15%.
〔製造例３：霊芝加工粉（混合粉末）の製造〕
製造例１で製造した霊芝の微粉末、及び製造例２で製造したエキス粉末を２：１の割合で混合し、混合粉末を得た。
[Production Example 3: Production of Reishi processed powder (mixed powder)]
The fine powder of ganoderma lucidum produced in Production Example 1 and the extract powder produced in Production Example 2 were mixed at a ratio of 2:1 to obtain a mixed powder.
なお、比較例１は、原体種Ａを栽培条件Ｐで栽培して得られた霊芝原体から製造した混合粉末である。実施例１は、原体種Ａを栽培条件Ｑで栽培して得られた霊芝原体から製造した混合粉末である。実施例２は、原体種Ｂを栽培条件Ｐで栽培して得られた霊芝原体から製造した混合粉末である。実施例３は、原体種Ｂを栽培条件Ｑで栽培して得られた霊芝原体から製造した混合粉末である。 Comparative Example 1 is a mixed powder produced from the original product of Ganoderma lucidum obtained by cultivating the original product species A under the cultivation condition P. Example 1 is a mixed powder produced from the original product of Ganoderma lucidum obtained by cultivating the original product species A under the cultivation condition Q. Example 2 is a mixed powder produced from the original material of Ganoderma lucidum obtained by cultivating the original material species B under the cultivation condition P. Example 3 is a mixed powder produced from the original material of Ganoderma lucidum obtained by cultivating the original material species B under the cultivation condition Q.
〔霊芝加工粉（混合粉末）の評価〕
実施例１～３及び比較例１の混合粉末について、ガノデリン酸Ａ、ガノデリン酸Ｃ１、ガノデリン酸Ｃ２及びβ－グルカンの含有量を評価した。
[Evaluation of Reishi processed powder (mixed powder)]
The mixed powders of Examples 1 to 3 and Comparative Example 1 were evaluated for the contents of ganoderic acid A, ganoderic acid C1, ganoderic acid C2 and β-glucan.
ガノデリン酸Ａ、ガノデリン酸Ｃ１及び、ガノデリン酸Ｃ２は、ＬＣ／ＭＳ（液体クロマトグラフィー質量分析法）を用いた定量法により定量した。まず、混合粉末にメタノールを浸漬させて、メタノール抽出液を得て、分析試料とした。得られた分析試料をＬＣ－ＭＳ（液体クロマトグラフ質量分析装置）で分析して、測定結果を得た。 Ganoderic acid A, ganoderic acid C1, and ganoderic acid C2 were quantified by a quantitative method using LC/MS (liquid chromatography mass spectrometry). First, the mixed powder was immersed in methanol to obtain a methanol extract, which was used as an analysis sample. The resulting analytical sample was analyzed by LC-MS (liquid chromatograph-mass spectrometer) to obtain measurement results.
β－グルカンは、酵素法により定量した。まず、混合粉末にリン酸緩衝液及びプロテアーゼを添加し、ろ過したろ液にトリフルオロ酢酸を添加し加水分解を行った。得られた溶液を中和した後、ろ過し、ろ液に含まれるブドウ糖をグルコースオキシダーゼ法で定量した。得られた測定値から、下記換算式に従い、β－グルカンの含有量を算出した。
β－グルカン（ｇ／１００ｇ）＝ブドウ糖（ｇ／１００ｇ）×０．９
β-Glucan was quantified by an enzymatic method. First, a phosphate buffer and protease were added to the mixed powder, and trifluoroacetic acid was added to the filtered filtrate for hydrolysis. After neutralizing the obtained solution, it was filtered and glucose contained in the filtrate was quantified by the glucose oxidase method. From the measured values obtained, the β-glucan content was calculated according to the following conversion formula.
β-glucan (g/100g) = glucose (g/100g) x 0.9
結果を表１に示す。表１中、各成分の含有量は、混合粉末１ｇあたりの含有量（ｍｇ）である。 Table 1 shows the results. In Table 1, the content of each component is the content (mg) per 1 g of mixed powder.
原体種Ａを栽培方法Ｐで栽培した霊芝原体から製造した霊芝加工粉（比較例１）と比べて、原体種Ａを栽培方法Ｑで栽培した霊芝原体から製造した霊芝加工粉（実施例１）、並びに原体種Ｂを栽培方法Ｐ及びＱで栽培した霊芝原体から製造した霊芝加工粉（実施例２及び３）は、ガノデリン酸Ａ、ガノデリン酸Ｃ１及びガノデリン酸Ｃ２の含有量が高まっており、霊芝の有する機能性が強化されたものであった。 Compared with the processed reishi mushroom powder (Comparative Example 1) produced from the reishi mushroom material obtained by cultivating the active ingredient species A according to the cultivation method P, the processed reishi mushroom produced from the reishi mushroom material obtained by cultivating the active ingredient species A according to the cultivation method Q. The powder (Example 1) and the processed powder (Examples 2 and 3) produced from the Ganoderma lucidum active material obtained by cultivating the active ingredient B by the cultivation methods P and Q were ganoderic acid A, ganoderic acid C1 and ganoderic acid The content of C2 was increased, and the functionality of Reishi mushroom was enhanced.
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019018629A JP7264657B2 (en) | 2019-02-05 | 2019-02-05 | Reishi processed powder |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019018629A JP7264657B2 (en) | 2019-02-05 | 2019-02-05 | Reishi processed powder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020124159A JP2020124159A (en) | 2020-08-20 |
| JP7264657B2 true JP7264657B2 (en) | 2023-04-25 |
Family
ID=72083083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019018629A Active JP7264657B2 (en) | 2019-02-05 | 2019-02-05 | Reishi processed powder |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP7264657B2 (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004196761A (en) | 2002-12-18 | 2004-07-15 | Bhn Kk | Neovascularization inhibitor |
| JP2005023021A (en) | 2003-07-02 | 2005-01-27 | Nonogawa Shoji Kk | Elastase inhibitor |
| JP2005104873A (en) | 2003-09-29 | 2005-04-21 | Nippon Menaade Keshohin Kk | Ganoderma lucidum extract by specific extraction method and method for producing the same |
| JP2013179861A (en) | 2012-02-29 | 2013-09-12 | National Institute Of Advanced Industrial Science & Technology | Ganoderma lucidum fruit body containing active ingredient in high concentration, method for cultivating ganoderma lucidum fruit body, and processed ganoderma lucidum fruit body |
| JP2018070489A (en) | 2016-10-27 | 2018-05-10 | Tdk株式会社 | Melanin production inhibitor |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61194032A (en) * | 1985-02-23 | 1986-08-28 | Osaka Chem Lab | Pulverized coriolus versicolor containing large amount of ganoderic acid as useful component, and production thereof |
| JPH04304890A (en) * | 1991-04-01 | 1992-10-28 | Nitto Denko Corp | Production of ganoderic acids |
| JP2965490B2 (en) * | 1995-08-23 | 1999-10-18 | 株式会社バイオックス | Extraction method of Reishi Extract |
-
2019
- 2019-02-05 JP JP2019018629A patent/JP7264657B2/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004196761A (en) | 2002-12-18 | 2004-07-15 | Bhn Kk | Neovascularization inhibitor |
| JP2005023021A (en) | 2003-07-02 | 2005-01-27 | Nonogawa Shoji Kk | Elastase inhibitor |
| JP2005104873A (en) | 2003-09-29 | 2005-04-21 | Nippon Menaade Keshohin Kk | Ganoderma lucidum extract by specific extraction method and method for producing the same |
| JP2013179861A (en) | 2012-02-29 | 2013-09-12 | National Institute Of Advanced Industrial Science & Technology | Ganoderma lucidum fruit body containing active ingredient in high concentration, method for cultivating ganoderma lucidum fruit body, and processed ganoderma lucidum fruit body |
| JP2018070489A (en) | 2016-10-27 | 2018-05-10 | Tdk株式会社 | Melanin production inhibitor |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020124159A (en) | 2020-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100962587B1 (en) | Fermentation method of natural plant material and herbal medicine, fermented product prepared by the above method and pharmaceutical composition, cosmetic composition and food composition containing the same | |
| JP2012143170A (en) | Medium for truffle cultivation, truffle mycelium, and truffle fruit body | |
| KR100922311B1 (en) | Double Culture Method of Chaga, Situation Mushroom, Ganoderma Lucidum Mushroom, Blossom Mushroom and Cordyceps Sinensis Producing Substances Containing Activated Sugar-related Compounds | |
| CN103083366B (en) | Glossy ganoderma-lentinus edodes stem solid state fermentation compound as well as preparation method and application thereof | |
| CN101524377A (en) | Composite of wall-breaking lucidum spore powder and cyclodextrin and preparation method thereof | |
| CN103315362A (en) | Poria cocos solid state fermentation functional beverage and its preparation method | |
| CN101194659A (en) | A kind of preparation method of agaricus blazei teabag | |
| CN1379082A (en) | Solid culture method of Antrodia camphorata, obtained solid culture and its products and uses | |
| SG174110A1 (en) | New ganoderma tsugae var. jannieae strain tay-i and biologically active biomass and extracts therefrom | |
| JPH03272663A (en) | Edible fat and oil food containing chlorella | |
| JP7264657B2 (en) | Reishi processed powder | |
| TWI614020B (en) | Composition of antrodia cinnamomea solid cultured mycelium and water/alcohol extract of fruiting body, and the use thereof in preparing healthy foods | |
| WO1995018626A1 (en) | A tonic drug made from basidiomycetes, algae, chinese herbal medicine and the method thereof | |
| KR20000018849A (en) | Health supplementation foods using cordyceps militaris and production process | |
| CN104381992A (en) | Eucommia ulmoides olive fungal substance sugar-free food and preparation method thereof | |
| JPH03224443A (en) | Food of chlorella-containing fats and oils | |
| KR101557894B1 (en) | Litsea japonica of oil as an active ingredient of lightening composition for improving and Method of Manufacture | |
| TWI381844B (en) | A method for isolating ganoderic acids from ganoderma growth bags | |
| CN105754865B (en) | Method for producing Ganoderma lucidum mycelium raw material by using mutant strain | |
| JP2022007501A (en) | Method for producing ganoderma lucidum processed powder, and ganoderma lucidum processed powder | |
| KR101254503B1 (en) | Methods for manufacturing Mycelium of Inonotus Obliquss with Buckwheat media | |
| JP3619189B2 (en) | Food composition and method for producing food composition | |
| TWI544875B (en) | Method of manufacturing an antioxidant animal feed using fermented wheat bran, and the use thereof | |
| KR101955895B1 (en) | Health functional food and a process for producing the same using Grifola | |
| KR20170119652A (en) | Health functional food and a process for producing the same using Grifola |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210924 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220913 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20221114 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230328 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230413 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7264657 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |